Free Trial
NYSE:INSP

Inspire Medical Systems Q2 2025 Earnings Report

Inspire Medical Systems logo
$129.54 -0.72 (-0.55%)
As of 03:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inspire Medical Systems EPS Results

Actual EPS
N/A
Consensus EPS
$0.22
Beat/Miss
N/A
One Year Ago EPS
N/A

Inspire Medical Systems Revenue Results

Actual Revenue
N/A
Expected Revenue
$214.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inspire Medical Systems Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 4, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

Inspire Medical Systems Earnings Headlines

Wall Street Zen Upgrades Inspire Medical Systems (NYSE:INSP) to Buy
This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
INSP Inspire Medical Systems, Inc. - Seeking Alpha
See More Inspire Medical Systems Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inspire Medical Systems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inspire Medical Systems and other key companies, straight to your email.

About Inspire Medical Systems

Inspire Medical Systems (NYSE:INSP) is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of sleep apnea. The company’s flagship product, the Inspire system, delivers targeted hypoglossal nerve stimulation therapy designed to maintain upper airway patency in patients with moderate to severe obstructive sleep apnea (OSA). Unlike traditional continuous positive airway pressure (CPAP) devices, Inspire’s minimally invasive implantable device offers an alternative therapy that automatically adjusts stimulation in response to breathing patterns during sleep.

Founded in the late 2000s and headquartered in Minneapolis, Inspire Medical Systems has secured regulatory approvals in the United States, Europe, Australia, New Zealand and other international markets. The company collaborates with a network of trained healthcare providers and accredited sleep centers to support patient evaluation, device implantation and ongoing therapy management. With growing clinical evidence and patient adoption, Inspire has established itself as a leader in the field of neurostimulation therapies for sleep-disordered breathing.

Under the leadership of President and Chief Executive Officer Niven Narain, Inspire Medical Systems has expanded its operational footprint and strengthened its research and development initiatives. The company continues to invest in clinical studies, physician education and patient support programs to enhance treatment outcomes and broaden the applicability of its technology. With its commitment to advancing sleep medicine and improving quality of life, Inspire Medical Systems remains at the forefront of innovative solutions for patients living with sleep apnea.

View Inspire Medical Systems Profile

More Earnings Resources from MarketBeat